Assessment of a Chronically Implanted Parasternally Delivered EV-ICD Lead (ASCEND EV) Study
Key facts
- Who runs it
- AtaCor Medical, Inc.
- Where
- Croatia, New Zealand, and Paraguay3 sites in 3 countriesChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 19 people enrolled
- Started
- 25 Feb 2025
- Expected to end
- 31 Dec 2028
- Type of study
- Interventional
- Treatments tested
- Atala™ lead
- Record updated
- 4 December 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 26 criteriaShow less
Who can take part
- At least 18 years old
- Class I or IIa indication for implantation of an ICD according to the ACC/AHA/HRS Guidelines or ESC guidelines
Who cannot take part
- Participation in any concurrent clinical study without prior written approval from the Sponsor
- Subjects on anticoagulation therapy that cannot be temporarily discontinued for the procedure
- Implanted with or planned implantation of any device which delivers current in the body, that may interfere with therapy delivery, including, but not limited to a pacemaker, or neurostimulator
- Prior sternotomy of any type, including but not limited to median, mini or clamshell
- Prior surgery with disruption of the lung, pericardium or connective tissue between the sternum and pericardium
- Inotropic therapy in past 180 days
- Any known conditions which may complicate the AtaCor EV-ICD Lead System implant procedure or prevent the subject from completing protocol testing through the 3-month follow-up visit
- Allergies to any device materials listed in the Instructions for Use (IFU)
- Known history of lung disease with FEV1 < 1.0 Liter; Device Related:
- Structural abnormalities of the heart that may increase risk of the study procedure or an obstructed/restricted pathway into the mediastinum
- Known significant anatomic derangement of or within the thorax (e.g., pectus excavatum, significant scoliosis) and associated with displacement of the heart or lungs or impeded mediastinal access
- History of thoracic radiation therapy, pneumothorax, pneumomediastinum or other medical treatments/conditions which may complicate the AtaCor EV-ICD Lead System implant procedure
- Known adhesions in the thorax or history of medical treatments, surgeries or conditions that increase the potential for adhesions in the thorax
- Surgically corrected congenital heart disease (not including catheter-based procedures); Cardiac Related:
- Subjects who require permanent bradycardia pacing or cardiac resynchronization therapy
- Known history of pericardial disease, pericarditis or mediastinitis
- Patients with a medical condition that precludes them from undergoing defibrillation testing:; Severe aortic stenosis; Current Intracardiac LA or LV thrombus; Severe proximal three-vessel or left main coronary artery disease without revascularization; Hemodynamic instability; Unstable angina; Recent stroke or transient ischemic attack (within the last 6 months); Known inadequate external defibrillation; LVEF < 20%; LVEDD >70 mm
- Inability or unwillingness to provide informed consent to participate in the Study
- Circumstances that may prevent data collection or completion of specified follow-up visits
- Presence or planned use of medical devices that introduce current into the body (e.g., pacemaker, LVAD, neurostimulator, etc.)
- Presence or planned use of a subcutaneous ICD lead, subcutaneous coils/arrays, epicardial patches or epicardial pace/sense leads
- Any known need for future MRI; Anatomy Related:
- BMI ≥ 35 kg/m2
- NYHA IV functional class in past 90 days
Where is this trial?
It has sites in 3 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
The ASCEND EV Study is a prospective, multi-center, single-arm, non-randomized study without concurrent or historical controls. The purpose of the study is to evaluate the Investigational Devices through at least 3-months of follow-up to inform the design of a subsequent pivotal clinical investigation.
Read full original descriptionShow less
The objectives of the study are to: 1) preliminarily validate safety and effectiveness of the Atala™ lead as a permanent ICD lead when used with a compatible ICD pulse generator, 2) evaluate suitability of clinical study testing methods and 3) inform statistically powered primary safety and effectiveness endpoints in a subsequent pivotal clinical investigation.
The group in the trial
- AtaCor EV-ICD Lead SystemTreatment being tested
Subjects implanted with the Atala™ lead
Treatment: Atala™ lead
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 4 December 2025